Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

American Science And Engineering, Inc. Receives $25 Million Follow-on Order For Z Portal And OmniView Systems To Secure Critical Infrastructure
American Science and Engineering, Inc. (AS&E®) (NASDAQ: ASEI), a leading worldwide supplier of innovative X-ray detection solutions, announced that it has received a $25 million follow-on order for a Middle East client for multiple Z Portal® cargo and vehicle screening systems and OmniView™ Gantry cargo inspection system to protect critical infrastructure in the region. AS&E"s Z Portal and OmniView systems will scan vehicles and trucks entering a high-risk facility in the Middle East for explosive threats and contraband.
generic viagra online
Cancer Risk May Be Greater With Insulin Analogue Glargine
The risk of cancer possibly increases if patients with diabetes use the long-acting insulin analogue glargine instead of human insulin. The Institute for Quality and Efficiency in Health Care (IQWiG), in collaboration with the "Wissenschaftliches Institut der AOK" (WIdO), the research institute of the German Local Health Care Fund, analysed the data of almost 130,000 patients with diabetes in Germany who had been treated with either human insulin or the insulin analogues lispro (trade name: Humalog), aspart (Novorapid) or glargine (Lantus) between January 2001 and June 2005.
News of the day
House Rejects Amendment To HHS Bill To Limit Funding To Planned Parenthood Clinics
The House on Friday voted 264-153 to approve its fiscal year 2010 Labor-HHS-Education spending bill (HB 3293) after voting on five amendments addressing price and policy issues, CQ Today reports. The bill would appropriate $730.5 billion. The Senate Appropriations Committee is scheduled to begin markup of its version of the bill on July 28.The House voted 183-247 to reject an amendment offered by Rep. Mike Pence (R-Ind.) that would have prohibited family planning funding through the Title X program to Planned Parenthood clinics. The House also voted 211-218 to reject an amendment by Rep. Mark Souder (R-Ind.) that would have stripped language to lift the ban on federal funding for needle-exchange programs. Lawmakers did approve an amendment offered by Rep. Darrell Issa (R-Calif.) to strip $5 million in funding for three NIH grants to study the HIV/AIDS risks associated with alcohol and substance use among sex workers in Asia and alcoholics in Russia (Wolfe, CQ Today, 7/24).
Sexual Health

Synosia Therapeutics Begins Phase I Trial Of A New Generation Treatment For Cognitive Impairment In Alzheimer's Disease And Schizophrenia

Synosia Therapeutics announced today that it has started a Phase I clinical trial of SYN-120, its new generation 5-HT6 antagonist under development for the treatment of cognitive impairment associated with Alzheimer"s and schizophrenia. The study will assess the safety and tolerability of single ascending doses of SYN-120 in healthy volunteers. Dr Ian Massey, Chief Executive Officer and President of Synosia Therapeutics said: "It"s a tribute to our team to be launching this study within months of acquiring SYN-120 through our partnership with Roche. It demonstrates our ability to efficiently and rapidly initiate and conduct clinical trials and to shorten the product development cycle". Alzheimer"s is an incurable disease, predominantly occurring in the elderly. Driven by the ageing population, prevalence of the disease is expected to double by 2025. Industry analysts Lead Discovery state that revenues of approved Alzheimer"s disease drugs across major markets (US, Japan, France, Germany, Italy, Spain and the UK) totalled over $3bn in 2006, with revenues expected to exceed $5bn by 2012. Schizophrenia is a severe form of mental illness, affecting about 24 million people worldwide. Cognitive impairment has long been recognised as a core feature of schizophrenia. It is present in the majority of patients, independent of symptoms such as delusions and hallucinations, and a major cause of poor social and vocational outcome. There are currently no medications approved for the treatment of cognitive impairment in schizophrenia. About SYN-120 SYN-120, a potent and selective antagonist of the 5-HT6 receptor, was discovered by Roche and is now under development by Synosia for the treatment of cognitive impairment. Antagonism of 5-HT6 receptors, which are expressed exclusively in regions of the brain associated with cognition, results in increased concentrations of acetylcholine and glutamate in these regions. Currently, acetylcholinesterase inhibitors are the mainstay for treatment of Alzheimer"s. SYN-120 is anticipated to be more efficacious than the acetylcholinesterase inhibitors and also to be devoid of the side effects (e.g. nausea and vomiting) of this class that result from non-selective increases in acetylcholine in organs other than the brain. Preclinical studies in a variety of models have shown that 5-HT6 antagonists have the potential to help reverse the cognitive losses brought about by Alzheimer"s disease and to improve executive function in schizophrenics. Synosia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009